Shionogi & Co., Beat Consensus Estimates

Shionogi & Co., (SGIOY) reported earnings of $0.36 per share on revenue of $1.02 billion for the fiscal first quarter ended June 2026. The consensus earnings estimate was $0.18 per share. The company beat consensus estimates by 100.00% while revenue grew 48.37% on a year-over-year basis.

Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.